Literature DB >> 21033472

[In vivo efficacy of Ingavirin against pandemic A (H1N1/09)v influenza virus].

L N Shishkina, V E Nebol'sin, M O Skarnovich, A S Kabanov, A A Sergeev, U B Erdyneeva, O A Serova, O K Demina, A P Agafonov, E A Stavskiĭ, I G Drozdov.   

Abstract

Ingavirin was shown to be efficient in inhibition of the pandemic influenza virus strains A/California/04/2009 (H1N1)v, A/California/07/2009 (H1N1)v, A/Moscow/225/2009 (H1N1)v and A/Moscow/226/2009 (H1N1)v. as well as the influenza virus strain A/Aichi/2/68 (H3N2) in the lungs of the infected mice. After oral administration of Ingavirin the titers of the influenza virus strains in the lung homogenates lowered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21033472

Source DB:  PubMed          Journal:  Antibiot Khimioter        ISSN: 0235-2990


  5 in total

Review 1.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

2.  Long-term respiratory follow-up of H1N1 infection.

Authors:  Paul Zarogoulidis; George Kouliatsis; Nikolaos Papanas; Dionysis Spyratos; Theodoros C Constantinidis; Ioannis Kouroumichakis; Paschalis Steiropoulos; Maria Mabroudi; Dimitris Matthaios; Theodora Kerenidi; Nikolaos Courcoutsakis; Konstantinos Zarogoulidis; Efstratios Maltezos
Journal:  Virol J       Date:  2011-06-25       Impact factor: 4.099

Review 3.  Macrolide therapy in respiratory viral infections.

Authors:  Jin-Young Min; Yong Ju Jang
Journal:  Mediators Inflamm       Date:  2012-06-06       Impact factor: 4.711

Review 4.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

Review 5.  Progress of small molecular inhibitors in the development of anti-influenza virus agents.

Authors:  Xiaoai Wu; Xiuli Wu; Qizheng Sun; Chunhui Zhang; Shengyong Yang; Lin Li; Zhiyun Jia
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.